论文部分内容阅读
目的观察培朵普利联合比索洛尔治疗慢性充血性心衰的临床疗效。方法选2008年至2010年105例住院慢性充血性心衰患者随机分为培朵普利治疗组(n=56)和在培朵普利片基础上逐渐加量比索洛尔至最大耐受量对照组(n=49)。观察一年后两组左室舒张末期内径、左室收缩末期内径、左室射血分数(LVEF);心功能分级、6 min步行实验。结果一年后培朵普利联合比索洛尔组在临床症状有显著的效果(P<0.01);心功能分级;6 min步行距离、左室舒张末和收缩末内径、LVEF等方面较单独培朵普利组有优越性(P<0.01)。结论培朵普利联合比索洛尔较单独培朵普利治疗慢性充血性心衰有更优越的临床疗效。
Objective To observe the clinical efficacy of combination of propidium and bisoprolol in the treatment of chronic congestive heart failure. Methods A total of 105 hospitalized patients with chronic congestive heart failure from 2008 to 2010 were randomly divided into beideopril treatment group (n = 56) and gradually added bisoprolol to maximum tolerated dose Control group (n = 49). Left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular ejection fraction (LVEF), heart function grading and 6-min walking test were observed after one year. Results One year later, the effect of pepidopril combined with bisoprolol in clinical symptoms was significant (P <0.01); heart function grading; 6-minute walk distance, left ventricular end-diastolic diameter and end-systolic diameter, LVEF, Dopril group has superiority (P <0.01). Conclusion Petipril combined with bisoprolol has more superior clinical efficacy than bevacizumab alone in the treatment of chronic congestive heart failure.